Exact Sciences to acquire Thrive Earlier Detection for $2.15bn
Exact Sciences, a US molecular diagnostics company, has agreed to acquire Thrive Earlier Detection in a cash cum stock deal worth up to $2.15 billion, in a move to become a leading player in blood-based, multi-cancer screening. Based in Cambridge and Baltimore, Thrive Earlier Detection is a healthcare company focused on incorporating earlier cancer detection […]